Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

1.

Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.

Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV.

BJU Int. 2012 Nov;110(9):1252-6. doi: 10.1111/j.1464-410X.2012.11118.x. Epub 2012 May 4.

PMID:
22564379
[PubMed - indexed for MEDLINE]
2.

Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.

Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.

Urology. 2007 Sep;70(3):506-10.

PMID:
17905106
[PubMed - indexed for MEDLINE]
3.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

PMID:
22369348
[PubMed - indexed for MEDLINE]
4.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

PMID:
22540922
[PubMed - indexed for MEDLINE]
5.

The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.

Miyake H, Sakai I, Inoue TA, Hara I, Fujisawa M.

Urol Int. 2006;77(2):122-6.

PMID:
16888415
[PubMed - indexed for MEDLINE]
6.

Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.

Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV.

Cancer. 2006 Dec 1;107(11):2597-603.

PMID:
17039498
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
[PubMed - indexed for MEDLINE]
8.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.

PMID:
19540066
[PubMed - indexed for MEDLINE]
9.

Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.

Soga N, Onishi T, Arima K, Sugimura Y.

Int J Urol. 2007 Mar;14(3):192-6; discussion 197.

PMID:
17430253
[PubMed - indexed for MEDLINE]
10.

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. doi: 10.1016/j.ijrobp.2008.10.071. Epub 2009 Mar 14.

PMID:
19289266
[PubMed - indexed for MEDLINE]
11.

A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.

Prapotnich D, Cathelineau X, Rozet F, Barret E, Mombet A, Cathala N, Sanchez-Salas RE, Vallancien G.

World J Urol. 2009 Oct;27(5):627-35. doi: 10.1007/s00345-009-0393-1. Epub 2009 Feb 27.

PMID:
19247669
[PubMed - indexed for MEDLINE]
12.

Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Kobayashi M, Nukui A, Suzuki K, Kurokawa S, Morita T.

Int J Clin Oncol. 2011 Dec;16(6):630-6. doi: 10.1007/s10147-011-0232-4. Epub 2011 Apr 23.

PMID:
21512893
[PubMed - indexed for MEDLINE]
13.

Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.

Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.

BJU Int. 2006 Jun;97(6):1184-9.

PMID:
16686709
[PubMed - indexed for MEDLINE]
14.

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.

J Urol. 2007 Oct;178(4 Pt 1):1290-5. Epub 2007 Aug 14.

PMID:
17698136
[PubMed - indexed for MEDLINE]
15.

Combined modality treatment in the management of high-risk prostate cancer.

Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1352-9.

PMID:
15275720
[PubMed - indexed for MEDLINE]
16.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.

PMID:
22401922
[PubMed - indexed for MEDLINE]
17.

Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.

Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.

J Urol. 2008 Oct;180(4):1438-43; discussion 1443-4. doi: 10.1016/j.juro.2008.06.029. Epub 2008 Aug 16.

PMID:
18710743
[PubMed - indexed for MEDLINE]
18.

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.

D'Amico AV, Renshaw AA, Loffredo B, Chen MH.

Cancer. 2007 Oct 15;110(8):1723-8.

PMID:
17828774
[PubMed - indexed for MEDLINE]
Free Article
19.

Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.

Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, Widmark A, Angelsen A.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):55-61. doi: 10.1016/j.ijrobp.2010.01.072.

PMID:
20598453
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk